Shield Therapeutics PLC (STX)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

10.00p

Buy

10.50p

arrow-up0.00p (+0.00%)

Prices updated at 12 Dec 2025, 16:27 GMT

Prices minimum 15 mins delay

Prices in GBX

Shield Therapeutics PLC is focused on the development and commercialization of late-stage, hospital-focused pharmaceuticals. It is a specialty pharmaceutical company.

FTSE All-Share

-0.48%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Mr. Peter Hermann William Llewellyn-Davies

CEO

-

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

63

Head office

Northern Design Centre

Newcastle

United Kingdom

NE8 3DF

+44 1915118500

investorrelations@shieldtx.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Peter Hermann William Llewellyn-Davies Non-Executive Director, Vice Chairman	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Miton Asset Management Limited	8,300,297
Premier Miton UK Smaller Companies	8,300,297

Director dealings

Date chevron-l-regular chevron-r-regular	Action
13 Feb 2025	Purchase

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.